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ABSTRACT 
 
Background: This document provides clinical recommendations for the prevention of chronic 
obstructive pulmonary disease (COPD) exacerbations. It represents a collaborative effort 
between the European Respiratory Society (ERS) and the American Thoracic Society (ATS).  
 
Methods: Comprehensive evidence syntheses were performed to summarize all available 
evidence relevant to the guideline panel’s questions. The evidence was appraised using the 
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach 
and the results were summarized in evidence profiles. The evidence syntheses were discussed 
and recommendations formulated by a multi-disciplinary committee of COPD experts. 
 
Results: After considering the balance of desirable (benefits) and undesirable consequences 
(burden, adverse effects, cost), quality of evidence, feasibility, and acceptability of various 
interventions, the guideline panel made recommendations for mucolytic, long-acting 
muscarinic antagonist, phosphodiesterase-4 inhibitor, and macrolide therapy, as well as a 
conditional recommendation against fluroquinolone therapy. All of the recommendations 
were conditional, indicating that there was uncertainty about the balance of desirable and 
undesirable consequences of the intervention, and that well-informed patients may make 
different choices regarding whether to have or not have the specific intervention. 
 
Conclusion: The guideline summarises the evidence and provides conditional  
recommendations for pharmacologic therapy for the prevention of COPD exacerbations.  
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INTRODUCTION 
 
Prevention of exacerbations is a key objective in COPD management. There are patients with 
COPD that are prone to suffer from recurrent exacerbations (1) and they experience a more 
severe impairment in health status (2,3). Moreover, patients with recurrent hospitalizations 
for exacerbations have a reduced survival (4). Although no definitive evidence exists about the 
impact of prevention of exacerbations of COPD in reducing mortality, treatments that 
effectively reduce the frequency and/or the severity of exacerbations may have an impact on 
the progression and ultimately the prognosis of COPD.  
 
This guideline was a collaborative effort between the European Respiratory Society (ERS) and 
the American Thoracic Society (ATS). It employed a systematic review of the literature, 
followed by use of the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) (5) approach to develop recommendations that answer the following five 
questions: 
 
Question #1: Should mucolytics be prescribed to patients with stable COPD to prevent COPD 
exacerbations?  
 
Question #2: Are long-acting beta-agonists or long-acting muscarinic antagonists preferable in 
patients with stable COPD to prevent COPD exacerbations? 
 
Question #3: Should roflumilast be prescribed to patients with stable COPD, a history of COPD 
exacerbations, and chronic bronchitis to prevent COPD exacerbations?  
 
Question #4: Should fluoroquinolones be prescribed to patients with stable COPD to prevent 
COPD exacerbations?  
 
Question #5: Should macrolides be prescribed to patients with stable COPD to prevent COPD 
exacerbations?  
 
This ERS/ATS guideline focuses on the prevention of COPD exacerbations. A separate ERS/ATS 
guideline was recently published that addresses the management of COPD exacerbations (6). 
We accepted other evidence-based evaluations of certain established therapies and did not 
seek to repeat the analyses already undertaken. Our role is to update and address gaps in the 
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existing evidence. Other therapies are effective and might be preferred to those we address 
here; e.g. smoking cessation or dual bronchodilator therapy, which were not considered within 
the time frame of this task force. 
 
METHODS 
 
The methodology followed for the development of this document regarding formulation of 
questions, rating the important outcomes, study selection, evidence synthesis and formulating 
and grading the evidence, has been described in detail in the previous publication of the 
guideline on treatment of COPD exacerbations (6) and can be found in the online supplement. 
Some important aspects of the methodology are summarised below: 
 
Group composition 
The guideline panel co-chairs (JAW, JAK) were selected by the European Respiratory Society 
(ERS) and American Thoracic Society (ATS). They led all aspects of project management and 
selected the panellists, which included 11 clinicians with experience in COPD management and 
research. In addition, there were two methodologists (TT, DR) and a clinician-methodologist 
(KCW). The lead methodologist (TT) identified and collected the evidence, performed the 
evidence syntheses, constructed the evidence profiles, and ensured that all the 
methodological requirements were met, with assistance from the other methodologists. The 
co-chairs and panellists discussed the evidence and formulated the recommendations; the 
methodologists did not participate in the development of recommendations. All panel 
members were required to disclose their conflicts of interest. Being an author of a publication 
reporting the effect of an intervention in prevention of exacerbations was considered as a COI. 
At least 50% of the co-chairs and 50% of the panel were required to be free from conflicts of 
interest. Individuals with potential conflicts of interest took part in the discussions about the 
evidence but did not participate in the formulation of recommendations.  
 
Literature searches 
Our literature searches used the National Institute of Health and Clinical Excellence (NICE) 
guidelines as a starting point (7). For questions that were addressed in the 2004 NICE 
guidelines, we conducted literature searches in Medline, Embase, and the Cochrane Database 
of Systematic Reviews beginning in 2003. For questions that were addressed in the 2010 NICE 
guidelines, we conducted literature searches in the same databases beginning in 2009. Initial 
searches were conducted in January 2012 and then updated in June 2012, February 2013, and 
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September 2015. We used the same or similar search strategies as those used by NICE. To 
search Embase and Medline, we searched only the English speaking literature using the search 
strategy shown in the online supplement, whereas to search the Cochrane Database of 
Systematic Reviews, we used the search term, “chronic obstructive pulmonary disease”. 
 
 
Manuscript preparation 
The initial draft of the manuscript was prepared by the co-chairs, methodologists, and one 
panellist (MM). The lead methodologist wrote the content for the online supplement, which 
was edited by the co-chairs. Both the manuscript and the online supplement were reviewed, 
edited, and approved by all panel members prior to submission.  
 
RESULTS 
 
Question #1: Should mucolytics be prescribed to patients with stable COPD to prevent COPD 
exacerbations?  
 
Summary of the evidence 
We identified one relevant systematic review (8), which included four trials that met our 
inclusion criteria (9-12). Our own systematic review identified two additional trials (13,14). 
These six trials collectively informed the panel’s judgments (9-14).  
 
All six trials were randomized, placebo-controlled trials conducted in patients with COPD. 
Ninety-three percent of patients had moderate or severe airflow obstruction, defined as a 
post-bronchodilator forced expiratory volume in one second (FEV1) to forced vital capacity 
(FVC) ratio (FEV1/FVC) <0.70 and an FEV1 30-79%. Three trials enrolled patients with COPD 
who had a history of at least two exacerbations per year during the previous two years 
(9,12,14), one trial enrolled patients with COPD who had a history of at least one exacerbation 
per year during the previous year (10), and two trials enrolled patients with COPD regardless 
of whether or not that had any exacerbations during the previous year (11,13).  Mucolytic 
agents included N-acetylcysteine in four trials (9,11,13,14), ambroxol in one trial (10), and 
carbocisteine in one trial (12). Four trials administered mucolytic therapy for one year 
(10,12,14,15) and two trials administered mucolytic therapy for three years (11,13).  
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The guideline panel identified a priori four outcomes as “critical” to guide the formulation of 
treatment recommendations; three other outcomes were considered “important”. The critical 
outcomes included the rate of COPD exacerbations, proportion of patients having at least one 
COPD exacerbation, hospitalizations, and quality of life, while the important outcomes 
included mortality, adverse events, and amount of sputum production.   
 
When the data were pooled via meta-analysis (see Evidence Profile #1), mucolytic therapy 
decreased the likelihood of hospitalization (14.1% versus 18.1%; RR 0.76, 95% CI 0.59 to 0.97), 
indicating that 25 patients needed to be treated with mucolytics to prevent one 
hospitalization. When we segregated the analysis based upon dosage, the absolute and 
relative decreases in hospitalizations were similar among patients who received high-dose or 
low-dose mucolytic therapy compared with both doses pooled together, but due to smaller 
number of patients in each group, the confidence intervals widened to include no significant 
effect of the drug. 
 
The effect of mucolytic therapy on COPD exacerbations varied according to the method of 
measurement. Mucolytic therapy reduced the relative rate of exacerbations when assessed as 
the number of exacerbations per patient-year (rate ratio 0.79, 95% CI 0.65-0.95), although the 
absolute rate reduction was small (rate difference of 0.38 fewer exacerbations per patient-
year, 95% CI 0.23 fewer to 0.54 fewer). The reduced rate of COPD exacerbations was largely 
attributable to high-dose mucolytic therapy (rate ratio 0.69, 95% CI 0.50-0.94), as trials that 
used low-dose mucolytic therapy did not find a significant relative rate reduction (rate ratio 
0.87, 95% CI 0.66-1.14). Mucolytic therapy had no effect on COPD exacerbations when 
assessed as the proportion of patients who remained exacerbation-free (34.1% versus 32.4%; 
RR 1.06, 95% CI 0.95 to 1.19).  
 
Mucolytic therapy had no demonstrable effect on mortality (1.3% versus 1.1%; RR 1.15, 95% CI 
0.55 to 2.43) or adverse events (26.9% versus 24.2%; RR 1.11, 95% CI 0.91 to 1.35). The effect 
on quality of life could not be estimated via meta-analysis and the individual studies provided 
inconsistent results. For all outcomes, the estimated effects did not change substantially when 
the trials were pooled according to whether or not a history of exacerbations was required for 
enrollment. 
 
Of note, we were unable to review one potentially relevant trial (15); as this study included 
patients with chronic bronchitis, and we were not able to assess it ourselves, we decided not 
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to include it in the evidence tables. We conducted sensitivity analyses to determine if the trial 
would have significantly affected the results and determined that the measured outcomes did 
not differ substantially whether the trial was included or excluded.  
 
Benefits: Mucolytic therapy reduced hospitalizations. Mucolytic therapy also reduced the 
number of COPD exacerbations per patient-year (an effect largely attributable to high-dose 
therapy), but not the proportion of patients who remained exacerbation-free. 
 
Harms: None identified; there was no evidence that mucolytic therapy increased adverse 
events. 
 
Other considerations: The overwhelming majority of patients had moderate or severe airflow 
obstruction; few patients had mild or very severe airflow obstruction. There was no 
information in any of the trials on the quantity of sputum production. In addition, the 
outcomes were limited by imprecise estimates, inconsistent results among the primary 
studies, or both; these limitations diminished the panel’s confidence in the estimated effects. 
A systematic review was published following the completion of our evidence synthesis (16). 
The results support that mucolytic therapy may reduce the frequency of COPD exacerbations 
but raised the possibility that patients with more severe obstruction may require higher doses 
than those with less severe obstruction.  
 
Conclusions and research needs 
Mucolytic therapy (N-acetylcysteine, ambroxol, carbocisteine) reduces the likelihood of 
hospitalization and, when given in high doses, may also reduce COPD exacerbations. No effect 
on mortality was shown, although there was a very low number of deaths in the trials to 
definitively determine the effect on mortality. Similarly, there is no evidence that mucolytic 
therapy increases adverse effects or alters quality of life. The effects of mucolytic therapy in 
patients with mild or very severe COPD are important research needs, as the findings will help 
define the patient population most likely to benefit from mucolytic therapy. Since most of the 
trials used N-acetylcysteine, additional research is needed to determine if ambroxol and 
carbocisteine have similar effects. As some of the studies included patients who were not on 
optimal inhaled therapy, the efficacy of mucolytics on top of maximal inhaled treatment has 
yet to be clearly established. 
 
What others are saying 
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The 2010 NICE Guidelines (7) recommended not to use mucolytic drugs routinely to prevent 
exacerbations in patients with stable COPD. The 2011 GOLD strategy document (17) stated 
that “although a few patients with viscous sputum may benefit from mucolytics, the overall 
benefits seem to be very small, and the widespread use of these agents cannot be 
recommended at present”. The 2015 ACCP/CTS Guidelines recommended N-acetylcysteine 
treatment for patients with moderate to severe COPD and a history of two or more 
exacerbations during the previous two years (18). 
 
 
ERS/ATS Recommendation 
For patients who have COPD with moderate or severe airflow obstruction and exacerbations 
despite optimal inhaled therapy, we suggest treatment with an oral mucolytic agent to prevent 
future exacerbations (conditional recommendation, low quality of evidence).  
 
Remarks 
Moderate or severe airflow obstruction is defined as an FEV1/FVC <0.70 and an FEV1 of 30 to 
79%. The beneficial effect of mucolytic therapy on the rate of COPD exacerbations was driven 
by trials that administered high-dose mucolytic therapy (e.g., N-acetylcysteine 600 mg twice 
daily).  
 
Values and preferences 
This recommendation places a high value on avoiding hospitalizations and a lower value on the 
cost and burden of taking daily medication. 
 
 
Question #2: Are long-acting beta-agonists or long-acting muscarinic antagonists preferable 
in patients with stable COPD to prevent COPD exacerbations? 
 
Summary of the evidence 
Our systematic review identified two relevant trials (19,20).  The first trial compared once daily 
tiotropium to once daily indacaterol (19). The second trial compared once daily tiotropium to 
twice daily treatment with salmeterol (20). Both trials were conducted over one year and 
required that patients had at least one COPD exacerbation during the past year. The 
overwhelming majority of patients had moderate or severe airflow obstruction, defined as a 
post-bronchodilator FEV1/FVC <0.70 and an FEV1 30 to 79%. 
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The guideline panel identified a priori six outcomes as “critical” to guide the formulation of 
treatment recommendations; two other outcomes were considered “important”. The critical 
outcomes included mortality, frequency of COPD exacerbations, hospitalizations, adverse 
events, quality of life, and FEV1, while the important outcomes included dyspnea and exercise 
tolerance.   
 
When the trials were pooled via meta-analysis (see Evidence Profile #2), patients who 
received a long-acting muscarinic antagonist (LAMA) were less likely to have one or more 
moderate to severe COPD exacerbations (30.9% versus 34.6%, RR 0.89, 95% CI 0.85-0.94). In 
addition, there was a trend in patients who received a LAMA to have fewer severe adverse 
effects (14.7% versus 16.1%, RR 0.91, 95% CI 0.84 to 1.0). There was no difference in mortality.  
 
One of the trials additionally reported that patients who received a LAMA were less likely to 
have a severe COPD exacerbation requiring hospitalization (7.1% versus 9.2%, RR 0.77, 95% CI 
0.66-0.90) and had greater improvement in their FEV1 from baseline (mean difference +19 mL, 
95% CI +11.34 mL to +28.66 mL) (20). The trial also found no difference in the quality of life, 
magnitude of improved dyspnea, or proportion of patients with less dyspnea. 
 
Benefits: Patients who received a LAMA were less likely to have one or more moderate to 
severe COPD exacerbations, were less likely to have a severe exacerbation requiring 
hospitalization, and had greater improvement in the FEV1 than patients who received a LABA.  
 
Harms: There was a trend toward more severe adverse events among patients who received a 
LABA than among those who received a LAMA. 
 
Other considerations:  The overwhelming majority of patients had moderate or severe airflow 
obstruction and there were no data from patients who had not had an exacerbation during the 
previous year. In addition, one outcome that the panel considered important (i.e., exercise 
tolerance) was not reported in either study. For several outcomes, the panel’s confidence in 
estimating the relative effects of LABA versus LAMA treatment was diminished by imprecision 
(i.e., wide confidence intervals). 
 
Conclusions and research needs 
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LAMA therapy reduces the likelihood of moderate to severe exacerbations compared to LABA 
therapy. It may be associated with fewer adverse events, however, additional data are needed 
to confirm or exclude this possibility. A differential effect of the agents on mortality has not 
been shown, although there were very few deaths in the trials to definitively confirm or 
exclude such an effect. The effects of LAMA vs LABA therapy in patients with mild or very 
severe COPD requires additional research. Additional data are also required to determine the 
difference in the effects of LAMA vs LABA therapy on mortality and adverse effects, as well as 
to determine the comparative effects of these two agents on other important clinical 
outcomes.  
 
What others are saying 
The 2010 NICE Guidelines (7) state, “In people with stable COPD who remain breathless or 
have exacerbations despite using short-acting bronchodilators as required, offer the following 
as maintenance therapy.  If FEV1 ≥ 50% predicted: either long-acting beta2 agonist (LABA) or 
LAMA.  If FEV1 < 50% predicted: either LABA with an inhaled corticosteroid (ICS) in a 
combination inhaler, or a LAMA.” The 2011 GOLD strategy document (17) recommend either a 
LAMA or a combined inhaled corticosteroid / LABA  (but not LABA monotherapy) for patients 
with GOLD spirometry class 3 or 4 obstruction and either two or more exacerbations per year 
or one or more exacerbation requiring hospitalization.  The 2015 ACCP/CTS Guidelines (18) 
stated, “in patients with moderate to severe COPD, we recommend the use of LAMAs 
compared with LABAs to prevent moderate to severe acute exacerbations of COPD.” 
 
ERS/ATS Recommendation  
In patients who have COPD with moderate or severe airflow obstruction and a history of one 
or more COPD exacerbations during the previous year, we recommend that a LAMA be 
prescribed in preference to LABA monotherapy to prevent future exacerbations (strong 
recommendation, moderate quality of evidence).  
 
Remarks 
Moderate or severe airflow obstruction is defined as an FEV1/FVC <0.70 and an FEV1 of 30 to 
79%.  
 
Values and preferences 
This recommendation places a high value on reducing the likelihood of a COPD exacerbation 
and a lower value on symptomatic relief, the burden of taking daily medication, and cost.  
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Question #3: Should roflumilast be prescribed to patients who have stable COPD with a 
history of COPD exacerbations and chronic bronchitis to prevent COPD exacerbations?  
 
Summary of the evidence 
The guideline panel made an a priori decision to look at the effects of roflumilast exclusively in 
patients who had chronic bronchitis. The rationale for focusing on this patient population was 
that initial trials conducted in patients with or without chronic bronchitis found only a small 
decrease in the exacerbation rate (21,22); however, a subsequent subgroup analysis found a 
much larger reduction in the exacerbation rate among patients with chronic bronchitis (22). 
 
Our systematic review identified three trials that compared roflumilast to placebo in patients 
with stable COPD, a history of COPD exacerbations, and chronic bronchitis (23,24); two of the 
trials were reported together (23). Sixty-eight percent of patients had severe airflow 
obstruction, defined as a post-bronchodilator FEV1/FVC <0.70 and FEV1 30-49%, and 31% of 
patients had very severe airflow obstruction, defined as a post-bronchodilator FEV1/FVC <0.70 
and FEV1 <30%. Two of the trials required participants to have had one or more COPD 
exacerbations during the previous year (23) and one trial required participants to have had 
two or more COPD exacerbations during the previous year (24).  All three trials administered 
roflumilast for one year (23,24).  
 
The guideline panel identified a priori six outcomes as “critical” to guide the formulation of 
treatment recommendations; three other outcomes were considered “important”. The critical 
outcomes included rate of COPD exacerbations, proportion of patients having at least one 
COPD exacerbation, time to first COPD exacerbation, mortality, adverse events, and 
cardiovascular events;  other important outcomes included changes in quality of life, FEV1, and 
FVC.   
 
When the data were pooled via meta-analysis (see Evidence Profile #3), roflumilast therapy 
decreased the number of moderate or severe exacerbations per patient-year (rate ratio 0.85, 
95% CI 0.78-0.91), as well as proportion of patients who had an exacerbation (21.4% versus 
25.2%, RR 0.85, 95% CI 0.78 to 0.94). Roflumilast also increased time to next exacerbation 
(Hazard ratio 0.88, 95% CI 0.81 to 0.96). While these effects were relatively modest when the 
three trials were pooled together and analyzed, the largest and most recent trial found a larger 
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reduction in the number of severe exacerbations (defined a severe exacerbation as one 
requiring hospitalization or resulting in death)  per patient-year despite concomitant therapy 
with an ICS/LABA (rate ratio 0.76, 95% CI 0.60-0.95) (24); the trial. 
 
The meta-analysis also demonstrated that patients who received roflumilast therapy had a 
larger increase in their post-bronchodilator FEV1 (mean difference 56.29 mL, 95% CI 45.45 mL  
to 67.14 mL) and FVC (mean difference 98.45 mL, 95% CI 79.35 mL to 117.55 mL). Roflumilast 
therapy had no effect on mortality (2.4% versus 2.4%, RR 0.99, 95% CI 0.70 to 1.42), adverse 
events (67.4% versus 60.9%, RR 1.11, 95% CI 1.06 to 1.15), or cardiovascular events (5.4% 
versus 4.9%, RR 1.11, 95% CI 0.88 to 1.40).  
 
While the trials that we selected found no evidence of increased adverse events or 
cardiovascular events among patients who received roflumilast, the panel decided to broaden 
its selection criteria for these outcomes only. Specifically, we decided to include data from the 
trials that we had excluded from our systematic review because their duration was less than 
one year. The rationale was that whereas benefits may take a while to accrue, meaningful 
adverse effects often occur soon after the initiation of therapy and, therefore, would be 
detectable in the shorter trials. A Cochrane systematic review included all of the relevant trials 
(25). Premature treatment discontinuation due to adverse effects was more common with 
roflumilast than placebo (14.9% versus 9.0%; risk ratio 1.80, 95% CI 1.58 to 2.04).  The most 
common adverse effects were diarrhea (9.7% versus 2.7%; risk ratio 3.96, 95% CI 3.20 to 4.89), 
nausea (4.8% versus 1.4%; risk ratio 3.54, 95% CI 2.63 to 4.78), weight loss (8.4% versus 2.3%; 
risk ratio 3.94, 95% CI 3.11 to 5.00), psychiatric disorders including anxiety and depressive 
symptoms (7.1% versus 3.5%; risk ratio 2.13, 95% CI 1.79 to 2.54), and sleep 
disturbance/insomnia (3.1% versus 1.1%; risk ratio 2.88, 95% CI 2.15 to 3.86).  Mortality was 
rare, with no significant difference (<2% in both the roflumilast and placebo groups). 
 
Benefits: Roflumilast therapy reduced the number of exacerbations per patient-year, an effect 
that was particularly strong for severe exacerbations. It also decreased the proportion of 
patients who developed an exacerbation, prolonged the time to next exacerbation, and 
modestly increased both FEV1 and FVC. 
 
Harms: Adverse events were not increased in our systematic review; however, an independent 
systematic review that included trials with shorter durations demonstrated that patients 
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receiving roflumilast were more likely to prematurely discontinue treatment and develop 
diarrhea, nausea, weight loss, psychiatric disturbances, insomnia, or sleep disturbances.  
 
Other considerations: The majority of patients had severe or very severe airflow obstruction, 
in contrast to the evidence reviewed for mucolytic therapy and LABA versus LAMA therapy 
that was predominately comprised of patients with moderate or severe airflow obstruction. 
Several outcomes were limited by imprecise estimates, which diminished the panel’s 
confidence in those estimated effects. None of the trials measured quality of life as an 
outcome. 
 
Conclusions and research needs 
Roflumilast therapy reduces COPD exacerbations, particularly severe exacerbations, and 
modestly improves lung function. No effect on mortality was evident, although there were too 
few deaths in the trials to definitively confirm or exclude an effect on mortality. Roflumilast 
therapy increases the risk of gastro-intestinal, sleep, and psychiatric adverse effects in less 
than 10% of patients.  The effect of roflumilast therapy in patients with mild or moderate 
airflow obstruction remains an important research need.   
 
What others are saying 
The 2010 NICE Guidelines (7) did not address roflumilast therapy and a previous version stated 
that there was not enough evidence to make recommendations. The 2011 GOLD strategy 
document (17) mentioned that “roflumilast may be useful to reduce exacerbations for patients 
with an FEV1 <50% predicted, a history of chronic bronchitis, and frequent exacerbations.” The 
2015 ACCP/CTS Guidelines suggests roflumilast for patients with moderate to severe COPD 
with chronic bronchitis and a history of at least one exacerbation during the previous year 
(18). 
 
ERS/ATS Recommendation:  
In patients who have COPD with severe or very severe airflow obstruction, symptoms of 
chronic bronchitis, and exacerbations despite optimal inhaled therapy, we suggest treatment 
with roflumilast to prevent future exacerbations (conditional recommendation, moderate 
quality of evidence).  
 
Remarks: 
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Severe or very severe airflow obstruction is defined as an FEV1/FVC <0.70 and an FEV1 of 
<50%.  
 
Values and preferences:  
This recommendation places a high value on the prevention of exacerbations and a lower 
value on the burden, cost, and adverse effects of taking a daily medication. 
 
 
Question #4: Should fluoroquinolones be prescribed to patients with stable COPD to prevent 
COPD exacerbations? 
 
Summary of the evidence 
We identified one trial that met our inclusion criteria (26). The trial was a randomized, 
placebo-controlled trial conducted in adults who had COPD (FEV1/FVC <0.70), chronic 
bronchitis, and at least two exacerbations per year during the previous year. Twenty-one 
percent of patients had moderate airflow obstruction (pre-bronchodilator FEV1 50-80%), 
43.9% had severe airflow obstruction (pre-bronchodilator FEV1 30-49%), and 26.0% had very 
severe airflow obstruction (pre-bronchodilator FEV1 <30%). Participants received either 
moxifloxacin 400 mg or placebo once daily for five days, repeated every eight weeks for a total 
of six courses administered over 48 weeks. This trial informed the guideline panel’s 
judgements.  
 
The guideline panel identified a priori five outcomes as “critical” to guide the formulation of 
treatment recommendations; two other outcomes were considered “important”. The critical 
outcomes included time to first COPD exacerbation, the proportion of patients who had one or 
more COPD exacerbation, hospitalization, mortality, and adverse events, while the important 
outcomes included changes in quality of life and the airway bacterial load.   
 
The trial found no definitive effects among patients who received a fluoroquinolone. There 
were, however, trends toward all of the following: fewer patients developing COPD 
exacerbations (47.3% versus 50.9%, risk ratio 0.93, 95% CI 0.83 to 1.05), a longer duration to 
first exacerbation (p=0.062), and improved quality of life (mean difference -1.20, 95% CI -3.01 
to 0.61) (see Evidence Profile #4). There were no differences in hospitalizations (23.0% versus 
23.4%, risk ratio 0.98, 95% CI 0.80 to 1.21), mortality (2.6% versus 2.9%, risk ratio 0.91, 95% CI 
0.45 to 1.78), or adverse events (82.1% versus 85%, risk ratio 0.97, 95% CI 0.92 to 1.02). When 
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the outcomes were re-analyzed using a per-protocol rather than an intention-to-treat 
approach, the results were similar.  
 
Benefits: Fluoroquinolone therapy conferred no definitive benefits.  
 
Harms: None identified; there was no evidence that fluoroquinolone therapy increased 
adverse events. 
 
Other considerations: The study reported a statistically significant improvement in COPD 
exacerbation rate when it was measured using an odds ratio; however, the same outcome 
showed only a trend toward improvement when measured using a risk ratio. The panel 
decided to use risk ratios to inform its judgements.  The study also reported a decreased COPD 
exacerbation rate in the subgroup of patients with mucopurulent sputum, but not in the 
subgroup without mucopurulent sputum; insufficient data was reported for us to re-analyze 
the subgroups using risk ratios. Several outcomes were limited by imprecise estimates, which 
diminished the panel’s confidence in the estimated effects.  
 
Conclusions and research needs 
Fluoroquinolone therapy has not been proven to prevent COPD exacerbations or improve 
other clinical outcomes. The estimated 3.6% absolute risk reduction and 7% relative risk 
reduction in COPD exacerbations would be clinically important if real, but these effects can be 
neither confirmed nor excluded due to the wide confidence intervals. Additional trials are 
necessary to determine the impact of fluoroquinolone therapy to prevent exacerbations. The 
panel concluded that patients who produce mucopurulent sputum are a particularly important 
subgroup to evaluate in future trials. 
 
What others are saying 
The 2010 NICE Guidelines (7) did not address fluoroquinolone therapy and a previous version 
stated that there was not enough evidence to recommend prophylactic antibiotic therapy in 
general. The 2011 GOLD strategy document (17) said that “the use of antibiotics, other than 
for treating infectious exacerbations of COPD and other bacterial infections, is currently not 
indicated.” The 2015 ACCP/CTS Guidelines did not address fluoroquinolone therapy (18). 
 
ERS/ATS Recommendation:  
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Fluoroquinolone therapy is not suggested as treatment for the sole purpose of preventing 
future COPD exacerbations (conditional recommendation, moderate quality of evidence).  
 
Values and preferences:  
This recommendation places a high value on avoiding unproven therapies (particularly when 
there is a risk of increasing bacterial resistance, which was of significant concern to the 
guideline panel) and a lower value on the potential to prevent COPD exacerbations.  
 
 
Question #5: Should macrolides be prescribed to patients with stable COPD to prevent COPD 
exacerbations?  
 
Summary of the evidence 
We identified one relevant systematic review (27), which included three trials that met our 
inclusion criteria (28-30). Our own systematic review identified an additional trial (31). These 
four trials collectively informed the panel’s judgments (28-31).  
 
All four trials were randomized, placebo-controlled trials conducted in patients with COPD. 
Two trials reported the severity of airflow obstruction as the mean FEV1 in each treatment 
arm, which ranged from 1.27 L to 1.47 L (28,29). The remaining two trials reported that 0.4% 
of patients had mild airflow obstruction, 26.4% of patients had moderate airflow obstruction, 
40.6% of patients had severe airflow obstruction, and 32.6% of patients had very severe 
airflow obstruction, when defined as a post-bronchodilator FEV1 of ≥80%, 50 to 79%, 30 to 
49%, and <30%, respectively (30,31). One trial enrolled patients with COPD who had a history 
of at least three exacerbations during the previous year (31), one trial enrolled patients with 
COPD who had a history of at least one exacerbation during the previous year (30), and two 
trials enrolled patients with COPD regardless of whether or not that had any exacerbations 
during the previous year (28,29).  Macrolide regimens included erythromycin 200mg to 400mg 
daily (28), erythromycin 250mg twice daily (29), azithromycin 250mg daily (30), and 
azithromycin 500mg three times per week (44). All of the trials administered the macrolide for 
one year (28-31). 
 
The guideline panel identified a priori five outcomes as “critical” to guide the formulation of 
treatment recommendations; two other outcomes were considered “important”. The critical 
outcomes included the rate of COPD exacerbations, time to first exacerbation, mortality, 
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hospitalizations, and serious adverse events. Important outcomes included quality of life and 
acquisition of macrolide resistance.   
 
When the data were pooled via meta-analysis (see Evidence Profile #5), macrolide therapy 
decreased the rate of COPD exacerbations (rate ratio 0.76, 95% CI 0.68 to 0.86), although the 
absolute decrease was modest (rate difference 0.40 fewer exacerbations per patient-year, 95% 
CI 0.24 fewer to 0.55 fewer). Macrolide therapy also increased the time to first COPD 
exacerbation (mean difference 81.53 more days, 95% CI 53.29 more to 109.77 more). Of note, 
the largest trial performed subgroup analyses and found that the increase in the time to first 
COPD exacerbation varied in patients on the basis of smoking status and age.  There was a 
significant reduction in the risk of COPD exacerbations among past smokers, but not current 
smokers (comparing azithromycin vs. placebo in past smokers: relative hazard 0.65, 95%CI 0.55 
to 0.77; comparing azithromycin vs. placebo in current smokers, relative hazard 0.99, 95%CI 
0.71 to 1.38; p=0.03 for interaction) and among patients older than 65 years, but not younger 
patients (older than 65 years: relative hazard 0.59, 95% 0.57 to 0.74; 65 years or younger, 
relative hazard 0.84, 95%CI 0.68 to 1.04; p=0.02 for interaction) (30). Although not a pre-
specified outcome, macrolide therapy reduced the proportion of patients who developed an 
exacerbation (57% versus 68%, risk ratio 0.84, 95% CI 0.76 to 0.92) (30).  
 
Macrolide therapy improved quality of life, measured using the St. George’s Respiratory 
Questionnaire score. The improvement was seen across all domains: total (mean difference 
2.18 lower, 95% CI 1.53 lower to 2.82 lower), symptoms (mean difference 3.36 lower, 95% CI 
2.42 lower to 4.29 lower), activity (mean difference 1.82 lower, 95% CI 1.03 lower to 2.62 
lower), and impacts (mean difference 2.04 lower, 95% CI 1.28 lower to 2.81 lower). There was 
no demonstrable effect on mortality (2.7% versus 3.0%, risk ratio 0.90, 95% CI 0.48 to 1.69). 
Data on hospitalizations could not be pooled because the trials reported the outcome 
differently; individual trials found a trend toward a decreased rate of hospitalization due to 
COPD exacerbations (30) and no difference in the time to first hospitalization (31). The effects 
of macrolide therapy on acquisition of macrolide resistance and the proportion of 
exacerbations requiring hospitalization were uncertain due to inconsistent results.  
 
Our meta-analysis identified a trend toward fewer serious adverse events among patients who 
received macrolide therapy than among those who received placebo (28.3% versus 33%, risk 
ratio 0.86, 95% CI 0.74 to 1.01). While this suggests that macrolides are generally well 
tolerated, individual trials provide several reasons for caution. In the largest trial (the MACRO 
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trial), the most common adverse event that led to premature treatment discontinuation was a 
hearing decrement measured using audiometry performed by clinical research staff (25.4% 
versus 19.7%; risk ratio 1.29, 95% CI 1.04 to 1.61) (30). However, hearing as assessed by 
audiometry returned to baseline in about one-third of patients whether or not treatment was 
discontinued (21 out of 61 [34%] individuals after azithromycin was discontinued; 6 out of 19 
[32%] individuals after azithromycin was not discontinued; 14 out of 37 [38%] individuals after 
placebo was discontinued; and, 2 out of 8 [25%] individuals after placebo was not 
discontinued). These improvements in both the azithromycin and placebo groups, together 
with a lack of hearing-related adverse events in the COLUMBUS trial (which did not use 
audiometry to monitor participants) (31), raise questions about the clinical significance of the 
hearing decrements as measured by audiometry noted in the MACRO trial. Macrolides are 
known to cause ventricular arrhythmias that could be fatal, but the incidence with long-term 
azithromycin in COPD is unknown. The MACRO study demonstrated no increased risk of 
cardiac arrhythmias over a study period of one year with use of daily azithromycin compared 
to placebo, however patients with baseline QTC prolongation were excluded from 
participation in the study and other drugs known to increase QTC interval were prohibited to 
be used during the conduct of the trial. Though not part of our systematic review, a well-
known observational study that used a claims database suggests that the risk of a fatal 
ventricular arrhythmia due to a macrolide compared with amoxicillin is 1 in 4,100 among 
individuals at high cardiovascular risk and less than 1 in 100,000 among individuals at low 
cardiovascular risk (32); thus, the United States Food and Drug Administration (FDA) 
recommends careful review of patient-level risk factors for ventricular arrhythmias (e.g., a 
history of a prolonged QT interval, use of co-therapies that prolong the  QT interval) when 
using azithromycin (33). 
 
Benefits: Macrolide antibiotic therapy reduced the COPD exacerbation rate, reduced the 
proportion of patients who experience an exacerbation, increased the time to next 
exacerbation, and improved quality of life. 
 
Harms:  There was no evidence that macrolide therapy increased serious adverse events 
collectively, but there was an increased incidence of a hearing decrement measured by 
audiometry. The effect of macrolide therapy on the acquisition of macrolide-resistance was 
uncertain.   
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Other considerations: The overwhelming majority of patients had moderate, severe, or very 
severe airway obstruction; few patients with mild airway obstruction were studied. One trial 
(43) was much larger than the others and, therefore, drove the pooled results. Reduction in 
the risk of exacerbations may be limited to former smokers or older patients based on post-
hoc analyses of one trial.  The panel’s confidence in the estimated effects for most outcomes 
was limited by inconsistency across trials or wide confidence intervals due to few events. 
 
Conclusions and research needs 
Macrolide therapy reduces the rate of COPD exacerbations and the proportion of patients who 
experience a COPD exacerbation. It also increases the time to next exacerbation and improves 
quality of life, although the magnitude of latter is smaller than what is typically considered 
clinically significant. No effect on mortality has been shown, but there were too few deaths in 
the trials to definitively confirm or exclude an effect on mortality. Similarly, there is 
uncertainty about the risk of serious adverse effects of chronic macrolide therapy in COPD 
(e.g., fatal arrhythmias) and its effect on the acquisition of macrolide resistance is uncertain. 
These effects of macrolide therapy need to be confirmed, since most of the outcomes were 
driven by a single large trial. In particular, a better understanding of the impact of macrolide 
therapy on the acquisition of macrolide resistance and cardiovascular adverse effects is 
needed. In addition, it needs to be determined whether the effects are shared by all antibiotics 
or specific to macrolides. Also, head-to-head studies comparing the benefits and adverse 
effects of oral medications that reduce the risk of COPD exacerbations (e.g., long-term 
azithromycin vs. roflumilast or N-acetylcysteine) are needed; previously published studies have 
been limited to comparisons with placebo.  Finally, defining subgroups of patients who are 
more or less likely to benefit from macrolide therapy (e.g., by smoking status) is necessary to 
refine the appropriate target patient population for therapy. In any case, macrolide therapy 
should not be a first line treatment in COPD and should be considered in appropriately 
selected patients. 
 
What others are saying 
The 2010 NICE Guidelines (7) did not address macrolide therapy and a previous version stated 
that there was not enough evidence to recommend prophylactic antibiotic therapy in general. 
The 2011 GOLD strategy document (17) stated that “the use of antibiotics, other than for 
treating infectious exacerbations of COPD and other bacterial infections, is currently not 
indicated.” The 2015 ACCP/CTS Guidelines say, “For patients with moderate to severe COPD, 
who have a history of one or more moderate or severe COPD exacerbations in the previous 
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year despite optimal maintenance inhaler therapy, we suggest the use of a long-term 
macrolide to prevent acute exacerbations of COPD” (18). 
 
ERS/ATS Recommendation 
For patients who have COPD with moderate to very severe airflow obstruction and 
exacerbations despite optimal inhaled therapy, we suggest treatment with a macrolide 
antibiotic to prevent future exacerbations (conditional recommendation, low quality of 
evidence).  
 
Remarks 
Moderate to very severe airflow obstruction is defined as an FEV1/FVC <0.70 and a post-
bronchodilator FEV1 of ≤80%. Before prescribing macrolides, clinicians need to carefully 
consider patients’ cardiovascular risk factors particularly for ventricular arrhythmias. 
 
Values and preferences 
This recommendation places a high value on reducing COPD exacerbations and a lower value 
on the suspected but unproven risk of inducing macrolide resistance and the cost and burden 
of taking daily medication. 
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Evidence Profile # 1 
Comparison: Mucolytics vs. placebo for patients with COPD to prevent COPD exacerbations 
Bibliography: 9) Decramer M, Rutten-van Mölken M, Dekhuijzen PN, Fabbri L. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC 
Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365:1552-60; 10) Malerba M, Ponticiello A, Radaeli A, Bensi G, Grassi V. Effect of twelve-months therapy with 
oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther 2004; 17(1):27-34; 
11) Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, van Schayck O, van, Weel C. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic 
bronchitis. Respir Med 2009; 103(4):542-551; 12) Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, Yang L, Bai CX, Wang CZ, Chen BY, Shi Y, Liu CT, Chen P, Li Q, Wang ZS, Huang YJ, Luo ZY, 
Chen FP, Yuan JZ, Yuan BT, Qian HP, Zhi RC, Zhong NS. Effect of carbocisteine on acute exacerbation of chronicobstructive pulmonary disease (PEACE Study): a randomisedplacebo-controlled 
study. Lancet 2008; 371(9629):2013-2018; 13) Tse HN, Raiteri L, Wong KY, Yee KS, Ng LY, Wai KY, Loo CK, Chan MH. High dose N-acetylcysteine in stable COPD. The 1 year, double-blind, 
randomized, placebo-controlled HIACE study. Chest 2013; 144(1):106-118; 14) Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, Yao WZ, Ma LJ, Li X, Raiteri L, et al. Twice daily N-
acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Resp Med 2014; 2(3):187-94. 
Quality assessment No. of patients Effect 
Quality Importance 
No of 
studies 
Design 
Risk 
of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Mucolytics Placebo 
Relative 
(95% 
Confidence 
Interval) 
Absolute  
(95% Confidence Interval) 
Hospitalisations (proportion of patients hospitalized) 
     All doses of mucolytics 
3 
1
 randomised 
trials 
none serious 
2
 none serious 
3 
none 114/810  
(14.1%) 
150/827  
(18.1%) 
Risk Ratio  
0.76 (0.59 to 
0.97) 
44 fewer per 1000 will be 
hospitalised (from 5 fewer to 74 
fewer)
 
⊕⊕ΟΟ 
LOW 
CRITICAL 
     High-dose mucolytics (N-acetylcysteine 600 mg PO BID) 
2 
4 
randomised 
trials 
none none none serious 
3 
none 59/554 
(10.6%) 
81/560  
(14.5%) 
Risk Ratio  
0.73 (0.0.49 to 
1.11) 
39 fewer per 1000 will be 
hospitalised (from 74 fewer to 16 
more)
 
⊕⊕⊕Ο 
MODERATE 
CRITICAL 
     Low-dose mucolytics (N-acetylcysteine 600 mg PO qD) 
1 
5 
randomised 
trials 
none none none serious 
3 
none 55/256  
(21.5%) 
69/267  
(25.8%) 
Risk Ratio  
0.83 (0.61 to 
1.13) 
44 fewer per 1000 will be 
hospitalised (from 101 fewer to 34 
more)
 
⊕⊕⊕Ο 
MODERATE 
CRITICAL 
COPD exacerbation rate (exacerbations per patient-year) 
     All doses of mucolytics 
4 
6 
randomised 
trials 
none serious 
7
 none serious 
8
 none 1171 1185 Rate Ratio 0.79 
(0.65 to 0.95) 
 
-- ⊕⊕ΟΟ 
LOW 
CRITICAL 
3 
9 
randomised 
trials 
none serious 
10
 none none none 915 918 
-- 
Rate difference = 0.38 fewer 
exacerbations per patient-year 
(from 0.23 fewer to 0.54 fewer)  
⊕⊕⊕Ο 
MODERATE 
CRITICAL 
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     High-dose mucolytics (N-acetylcysteine 600 mg PO BID) 
2 
11 
randomised 
trials 
none serious 
12
 none serious 
8
 none 562 564 Rate Ratio 0.69 
(0.50 to 0.94) 
 -- 
 ⊕⊕ΟΟ 
LOW 
CRITICAL 
2 
11
 randomised 
trials 
none serious 
12
 none none none 562 564 
-- 
Rate difference = 0.49 fewer 
exacerbations per patient-year 
(from 0.09 fewer to 0.89 fewer) 
 CRITICAL 
     Low-dose mucolytics (N-acetylcysteine 600 mg PO qD, ambroxol 75 mg PO BID, and carbocisteine 500 mg PO TID) 
2 
13 
randomised 
trials 
none serious 
14
 none serious 
8
 none   Rate Ratio 0.87 
(0.66 to 1.14) 
 
-- ⊕⊕⊕Ο 
MODERATE 
CRITICAL 
1 
15
 randomised 
trials 
none none none none none   
-- 
Rate difference = 0.34 fewer 
exacerbations per patient-year 
(from 0.17 fewer to 0.51 fewer)  
 CRITICAL 
COPD exacerbations (proportion of patients with no exacerbations) 
5 
16 
randomised 
trials 
none none none none none 375/1098  
(34.1%) 
359/1107 
(32.4%) 
Risk Ratio  
1.06 (0.95 to 
1.19) 
19 more per 1000 will be exacerbation-
free (from 16 fewer to 62 more) 
⊕⊕⊕⊕ 
HIGH 
CRITICAL 
Quality of Life (change in the St. George’s Respiratory Questionnaire during treatment) (better quality of life indicated by lower values) 
4 
17 
randomised 
trials 
none very serious 
18 
none none none 1165 1179 not estimable 
19
 not estimable 
19 
⊕⊕ΟΟ 
LOW 
CRITICAL 
Adverse events (proportion of patients experiencing an adverse event) 
4 
17 
randomised 
trials 
none none none none none 149/553 
(26.9%) 
135/557  
(24.2%) 
Risk Ratio  
1.11 (0.91 to 
1.35) 
20 
27 more per 1000 will have an adverse 
event (from 22 fewer to 85 more) 
20 
⊕⊕⊕⊕ 
HIGH 
IMPORTANT 
Mortality (proportion of patients who died) 
5 
21 
randomised 
trials 
none none none serious 
5
 none 16/1267  
(1.3%) 
14/1281  
(1.1%) 
Risk Ratio  
1.15 (0.55 to 
2.43) 
2 more deaths per 1000 (from 5 fewer 
to 16 more) 
⊕⊕⊕Ο 
MODERATE 
IMPORTANT 
Decrease in sputum production 
0 
 
      
     IMPORTANT 
Notes : 
1 
Decramer 2005, Tse 2013, and Zheng 2014. 
2 
Large amount of heterogeneity across studies: for the mean difference, p- value (for heterogeneity) = 0.23 and I
2
 = 33%. 
3
 Wide confidence intervals: The ends of the confidence interval for the risk ratio will likely lead to different clinical decisions. 
4 
Tse 2013 and Zheng 2014. 
5 
Decramer 2005. 
6 
Decramer 2005, Zheng 2008, Tse 2013, and Zheng 2014. 
7 
Large amount of heterogeneity across studies: p- value (for heterogeneity) = 0.0004 and I
2
 = 84%. 
8 
Wide confidence intervals: The ends of the confidence interval for the rate ratio will likely lead to different clinical decisions. 
9 
Zheng 2008, Tse 2013, and Zheng 2014. 
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10 
Large amount of heterogeneity across studies: p- value (for heterogeneity) = 0.19 and I
2
 = 39%. 
11
 Tse 2013 and Zheng 2014. 
12 
Large amount of heterogeneity across studies: p- value (for heterogeneity) = 0.07 and I
2
 = 69%. 
13 
Decramer 2005 and Zheng 2008. 
14 
Large amount of heterogeneity across studies: p- value (for heterogeneity) = 0.002 and I
2
 = 89%. 
15 
Zheng 2008. 
16 
Malerba 2004, Zheng 2008, Schermer 2009, Tse 2013, and Zheng 2014. 
17
 Decramer 2005, Zheng 2008, Tse 2013, and Zheng 2014. 
18 
Large amount of heterogeneity across studies: for the mean difference, p- value (for heterogeneity) <0.00001 and I
2
 = 97%. 
19
 Decramer 2005 and Zheng 2014 did not report sufficient crude data to be included in the meta-analysis. When Zheng 2008 and Tse 2013 were pooled, the heterogeneity was very serious, 
indicating that these studies should not be pooled because doing so provides misleading results.  
20 
Tse 2013 and Zheng 2014. Decramer 2005 and Zheng 2008 reported the number of adverse events in each arm of the trial, not the number of patients experiencing an adverse event; therefore 
these trials were not included in the meta-analysis. 
21 
Decramer 2005, Schermer 2009, Tse 2013, Zheng 2008, and Zheng 2014. 
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Evidence Profile # 2 
 
Comparison: Long-acting beta agonists versus long-acting muscarinic agents for patients with COPD to prevent COPD exacerbations 
Bibliography: 19) Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-Van Molken MP, Beeh KM, Rabe KF, Fabbri LM, POET-COPD Investigators. Tiotropium versus salmeterol for the 
prevention of exacerbations of COPD. N Engl J Med 2011; 364(12):1093-103; 20) Decramer ML, Chapman, KR, Dahl R, Frith P, Devouassoux G, Fritscher C, Cameron R, Shoaib M, Lawrence D, 
Young D, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir 
Med 2013; 1(7):524-533. 
 
Quality assessment No of patients Effect 
Quality Importance 
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
LAMAs LABAs 
Relative 
(95% Confidence 
interval) 
Absolute                         (95% 
Confidence interval) 
Mortality (proportion of patients on treatment +30 days who died) 
2 
1 
randomised 
trials 
none 
 
 
none none serious 
2
 none 92/5425  
(1.7%) 
106/5390  
(2%) 
Risk Ratio 0.86 
(0.65 to 1.14) 
3 fewer per 1000 (from 7 fewer 
to 3 more) 
⊕⊕⊕Ο 
MODERATE 
 
CRITICAL 
COPD exacerbations (proportion of patients with at least 1 moderate/severe exacerbation) 
2 
1 
randomised 
trials 
 
none  none none none none 1624/5250 
(30.9%) 
1795/5189 
(34.6%) 
Risk Ratio 0.89 
(0.85 to 0.94) 
38 fewer per 1000 (from 21 
fewer to 52 fewer) 
⊕⊕⊕⊕ 
HIGH 
CRITICAL 
COPD exacerbations (proportion of patients having a severe exacerbation requiring hospitalisation) 
1 
3 
randomised 
trials 
 
none none none serious
 2
 none 262/3707  
(7.1%) 
336/3669  
(9.2%) 
Risk Ratio 0.77 
(0.66 to 0.9) 
21 fewer per 1000 (from 9 fewer 
to 31 fewer) 
⊕⊕⊕Ο 
MODERATE 
CRITICAL 
Severe adverse events (proportion of patients experiencing a severe adverse event) 
2 
1 
randomised 
trials 
none  none none none none 800/5425  
(14.7%) 
869/5390  
(16.1%) 
Risk Ratio 0.91 
(0.84 to 1) 
15 fewer per 1000 (from 26 
fewer to 0 more) 
⊕⊕⊕⊕ 
HIGH 
 
CRITICAL 
Quality of Life (change in the St. George’s Respiratory Questionnaire during treatment) (better quality of life indicated by lower values) 
1 
3 
randomised 
trials 
 
none none none none none 1325 1281 - Mean Difference 0.4 lower (1.56 
lower to 0.76 higher) 
⊕⊕⊕⊕ 
HIGH 
CRITICAL 
Forced expiratory volume in one second (mL) 
1 
3 
 
randomised 
trials 
 
none none none none none 1362 1324 - Mean Difference 19 greater 
(11.34 greater to 28.66 greater) 
⊕⊕⊕⊕ 
HIGH 
CRITICAL 
Dyspnoea (change in the Transition Dyspnea Index [TDI] during treatment) (less dyspnea indicated by higher values) 
1 
3 
randomised none none none none none 1332 1296 - Mean Difference 0.3 lower (0.57 ⊕⊕⊕⊕ IMPORTANT 
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trials 
 
to 0.03 lower) HIGH 
Exercise tolerance 
0 
 
           IMPORTANT 
1
 Vogelmeier C 2011 and Decramer ML 2013. 
2 
Wide confidence intervals: The ends of the confidence interval for the risk ratio will likely lead to different clinical decisions. 
3
 Decramer ML 2013. 
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Evidence Profile # 3 
  
Comparison: Roflumilast versus placebo for patients with COPD to prevent COPD exacerbations 
Bibliography: 23) M2-124 and M2-125, both reported by Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ et al. Roflumilast in symptomatic chronic obstructive 
pulmonary disease: two randomised clinical trials. Lancet 2009;374(9691):685-94. 24) Martinez FJ, Calverley PMA, Goehring UM. Effect of roflumilast on exacerbations in patients with severe 
chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT):a multicentre randomised controlled trial. Lancet 2015; 385(9971):857-866.  
 
Quality assessment No of patients Effect 
Quality Importance 
No of 
studies 
Design 
Risk 
of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Roflumilast Placebo 
Relative 
(95% 
Confidence 
interval) 
Absolute 
(95% Confidence interval) 
COPD exacerbations (exacerbations per patient-year) 
3
 
randomised 
trials 
none none none serious
1 
 
none 2506 2520 Rate ratio 0.85 
(0.78 to 0.92) 
Rate difference = 0.14 fewer 
exacerbations per patient-year 
(from 0.25 fewer to 0.03 fewer) 
⊕⊕⊕Ο 
MODERATE 
 
CRITICAL 
COPD exacerbations (proportion of patients with at least 1 moderate/severe exacerbation) 
3  randomised 
trials 
 
 
none none none serious
1
  none 537/2506  
(21.4%) 
636/2520  
(25.2%) 
Risk ratio 0.85 
(0.78 to 0.94) 
38 fewer per 1000 (from 15 fewer to 
56 fewer) 
⊕⊕⊕Ο 
MODERATE 
 
CRITICAL 
COPD exacerbations (time to first exacerbation, days) 
3 
 
randomised 
trials 
 
 
none none none none none 2506 2520 Hazard ratio 0.88 
(0.81 to 0.96) 
-- 
⊕⊕⊕⊕ 
HIGH 
CRITICAL 
Mortality (%) 
3  randomised 
trials 
 
 
none none none serious
1
 none 59/2506 
(2.4%) 
60/2520 
(2.4%) 
Risk ratio 0.99 
(0.70 to 1.42) 
0 fewer per 1000 (from 7 fewer to 
10 more) 
⊕⊕⊕Ο 
MODERATE 
CRITICAL 
Adverse events (%) 
3 randomised 
trials 
 
 
none none none none none 1688/2505 
(67.4%) 
1535/2521 
(60.9%) 
Risk ratio 1.11 
(1.06 to 1.15) 
67 more per 1000 (from 37 more to 
91 more) 
⊕⊕⊕⊕ 
HIGH 
 
CRITICAL 
Cardiovascular events (%) 
3  randomised none none none none none 136/2506  124/2520  Risk ratio 1.11 5 more per 1000 (from 6 fewer to ⊕⊕⊕⊕ CRITICAL 
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trials 
 
 
(5.4%) (4.9%) (0.88 to 1.40) 20 more) HIGH 
Change in quality of life (assessed via the St. George’s Respiratory Questionnaire) (Better indicated by lower values) 
0 
 
 
-- -- 
-- 
-- -- -- -- -- -- -- -- 
IMPORTANT 
Change in post-bronchodilator forced expiratory volume in one second, FEV1 (mL) (Better indicated by higher values) 
3
 
randomised 
trials 
 
 
none none none none none 2381 2441 
-- 
Mean difference 56.29 mL higher 
(45.45 mL higher to 67.14 mL 
higher) 
⊕⊕⊕⊕ 
HIGH 
IMPORTANT 
Change in post-bronchodilator forced vital capacity, FVC (mL) (Better indicated by higher values) 
3 
 
randomised 
trials 
 
 
none none none none none 2381 2441 - Mean difference 98.45 mL higher 
(79.35 mL higher to 117.55 mL 
higher) 
⊕⊕⊕⊕ 
HIGH 
IMPORTANT 
1
 Wide confidence interval: the ends of the confidence interval would lead to different clinical decisions 
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Evidence Profile # 4 
 
Comparison: Fluroquinolones vs. placebo for patients with COPD to prevent COPD exacerbations 
Bibliography: 27) Sethi S, Jones PW, Schmitt Terron M, Miravitlles M, Rubinstein E, Wedzicha JA, Wilson R, the PULSE Study Group. Pulsed moxifloxacin for the prevention of exacerbations of 
chronic obstructive pulmonary disease: a randomized controlled trial. Respiratory Research 2010; 11:10. 
 
Quality assessment No of patients Effect 
Quality Importance 
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Fluroquinolones Placebo 
Relative 
(95% 
Confidence 
interval) 
Absolute 
(95% Confidence 
interval) 
COPD exacerbations (proportion of patients with at least 1 moderate/severe exacerbation) 
1 randomised 
trials 
 
none none
 
 
  
none none none 269/569
1
 
(47.3%) 
295/580
1
 
(50.9%) 
Risk ratio 0.93 
(0.83 to 1.05)
1 
 ⊕⊕⊕⊕ 
HIGH 
CRITICAL 
Time to first COPD exacerbation (days) 
1 randomised 
trials 
 
none none
 
 none none none 569
2 
580
2 
Not estimable
3 
Not estimable
3 
⊕⊕⊕⊕ 
HIGH 
CRITICAL 
Hospitalisation (%) 
1 randomised 
trials 
none none
 
 none serious
4
 none 131/569
5
  
(23%) 
136/580
5
 
(23.4%) 
Risk ratio 0.98 
(0.8 to 1.21)
5 
5 fewer per 1000 
(from 47 fewer to 49 
more)
5 
⊕⊕⊕Ο 
MODERATE 
CRITICAL 
Mortality (%) 
1 randomised 
trials 
none none none serious
1
 none 15/569
6
  
(2.6%) 
17/580
6
  
(2.9%) 
Rate ratio 0.901 
(0.45 to 1.78)
6 
3 fewer per 1000 
(from 16 fewer to 23 
more)
6 
⊕⊕⊕Ο 
MODERATE 
CRITICAL 
Adverse events (%) 
1 randomised 
trials 
none none
 
 none none none 467/569  
(82.1%) 
493/580 
(85.0%) 
Rate ratio 0.97 
(0.92 to 1.02)
 
25 fewer per 1000 
(from 68 fewer to 17 
more)
 
⊕⊕⊕⊕ 
HIGH 
CRITICAL 
Change in quality of life (Assessed via the St. George’s Respiratory Questionnaire) (Better indicated by lower values) 
1 randomised 
trials 
none none none none none 503
7 
526
7 
- Mean difference 1.2 
lower (3.01 lower to 
0.61 higher)
7 
⊕⊕⊕⊕ 
HIGH 
IMPORTANT 
Reduction in airway bacterial load 
0 - 
 
- - - - - - - - - - 
IMPORTANT 
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1 
Derived by intention-to-treat analysis. Per-protocol analysis found 153/351 (43.6%) versus 190/387 (49.1%), Risk ratio 0.89 (95% CI 0.76- to 1.04). 
2
 For the intention-to-treat analysis: fluroquinolone (n=569), placebo (n=580). For the per-protocol analysis: fluroquinolone (n=351), placebo (n=387). 
3 
The trial did not provide estimates of the time to exacerbation in each arm in days; however, it reported a trend toward a longer duration to first exacerbation among patients who received 
fluroquinolones than placebo according to both intention-to-treat and per-protocol analyses. 
4
 Wide confidence intervals: The ends of the confidence intervals lead to different clinical decisions. 
5 
Derived by intention-to-treat analysis. Per-protocol analysis found 56/351 (16.0%) versus 54/387 (14.0%), Risk ratio 1.14 (95% CI 0.81 to 1.61). 
6 
Derived by intention-to-treat analysis. Per-protocol analysis found 1/351 (0.3%) versus 3/387 (0.8%), Risk ratio 0.36 (95% CI 0.04 to 3.43). 
7 
Derived by intention-to-treat analysis. Per-protocol analysis found fluroquinolone (n=569), placebo (n=580), mean difference -1.30 (95% CI -3.47 to 0.87). 
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Evidence Profile # 5 
 
Comparison: Macrolides vs. placebo for patients with COPD to prevent COPD exacerbations. 
Bibliography: 28) Suzuki T, Yanai M, Yamaya M, Satoh-Nakawaga T, Sekizawa K, Ishida S, Sasaki H. Erythromycin and common cold in COPD. Chest 2001;120(3):730-3; the time to 
exacerbation; 29) Seemungal TAR, Wilkinson TMA, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term Erythromycin Therapy Is Associated with Decreased Chronic Obstructive 
Pulmonary Disease Exacerbations. Am J Respir Crit Care Med 2008; 178:1139-1147; 30) Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr., Criner GJ, Curtis JL, Dransfield MT, Han MK, 
Lazarus SC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365(8):689-98; and 31) Uzun S, Djamin RS, Kluytmans JAJW et al. Azithromycin maintenance 
treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2014; 2: 361-368. 
 
Quality assessment № of patients Effect 
Quality Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
macrolide placebo 
Relative 
(95% 
Confidence 
interval) 
Absolute 
(95% Confidence 
interval) 
COPD exacerbation rate (exacerbations per patient-year) 
3 
1 
randomised 
trials  
none 
 
serious 
2 
none serious 
3 
none  658 660 Rate ratio 
0.76 
(0.68 to 0.86)  -- 
⨁⨁◯◯ 
LOW 
CRITICAL 
2 
4 
randomised 
trials  
none 
 
serious 
5 
none none none  605 604 
-- 
Rate difference 
0.40 fewer (0.24 
fewer to 0.55 
fewer) 
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
Time to first exacerbation (days) 
3 
1 
randomised 
trials  
none  none none none none  658 660 
--
 
Mean difference 
81.53 fewer (53.29 
fewer to 109.77 
fewer) 
⨁⨁⨁⨁ 
HIGH 
CRITICAL 
Hospitalisation 
3 
1
 randomised 
trials  
none  none none  serious 
3
 none  658 660 not estimable 
6 not estimable 
6
 
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
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Quality assessment № of patients Effect 
Quality Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
macrolide placebo 
Relative 
(95% 
Confidence 
interval) 
Absolute 
(95% Confidence 
interval) 
Serious adverse events 
3 
7 
randomised 
trials  
none  none none  serious 
5
 none  187/660 
(28.3%)  
217/658 
(33.0%)  
Risk ratio 
0.86 
(0.74 to 1.01)  
46 fewer per 1000 
(from 86 fewer to 3 
more)  
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
Mortality 
3 
7
 randomised 
trials  
none  none none  serious 
5
 none  18/660 
(2.7%)  
20/657 
(3.0%)  
Risk ratio 
0.90 
(0.48 to 1.69)  
3 fewer per 1000 
(from 17 fewer to 
23 more)  
⨁⨁⨁◯ 
MODERATE 
CRITICAL 
Acquisition of macrolide-resistant bacteria 
2 
3 
randomised 
trials  
none  serious 
8
 none  none none  605 604 not 
estimable 
9 not estimable 
9
 
⨁⨁⨁◯ 
MODERATE 
IMPORTANT 
Quality of Life (St. George’s Respiratory Questionnaire score) (Lower values indicate a better quality of life) 
Total 
2 
3
 randomised 
trials  
serious 
10
 
none none none  none  491  498 -  Mean difference 
2.18 lower 
(1.53 lower to 2.82 
lower)  
⨁⨁⨁◯ 
MODERATE 
IMPORTANT 
Symptoms 
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Quality assessment № of patients Effect 
Quality Importance 
№ of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
macrolide placebo 
Relative 
(95% 
Confidence 
interval) 
Absolute 
(95% Confidence 
interval) 
2 
3
 randomised 
trials  
serious 
10
 
none none none none  491  498 -  Mean difference 
3.36 lower 
(2.42 lower to 4.29 
lower) 
⨁⨁⨁◯ 
MODERATE 
IMPORTANT 
Activity 
2 
3
 randomised 
trials  
serious 
10
 
not serious  none none none  491  498 -  Mean difference 
1.82 lower 
(1.03 lower to 2.62 
lower 
⨁⨁⨁◯ 
MODERATE 
IMPORTANT 
Impacts 
2 
3
 randomised 
trials  
serious 
10
 
serious 
11 
none none none  491  498 -  Mean difference 
2.04 lower 
(1.28 lower to 2.81 
lower 
⨁⨁◯◯ 
LOW 
IMPORTANT 
1 
Seemungal 2008, Albert 2011, and Uzun 2014. 
2
 Inconsistency: I
2 
= 57%, phet = 0.10. 
3 
Wide 95% confidence intervals: the ends of the confidence interval would lead to different clinical decisions. 
4 
Albert 2011 and Uzun 2014. 
5 
Inconsistency: I
2 
= 85%, phet = 0.010. 
6 
The data could not be pooled because it was reported in different ways. Seemungal 2008 reported a non-significant decrease in the proportion of exacerbations that are severe enough to require 
hospitalization (7.4% versus 11.4%, risk ratio 0.66, 95% CI 0.27 to 1.65). Albert 2010 reported a non-significant reduction in the rate of hospitalization due to COPD (0.34 hospitalizations per patient-
year versus 0.49 hospitalizations per patient-year, hazard ratio 0.82, 95% CI 0.64 to1.07). Uzun 2014 reported a non-significant increase in the time to first hospitalization (282 days versus 258 days, 
p=0.48) and a non-significant decrease in the proportion of exacerbations that are severe enough to require hospitalization (29.8% versus 24%, risk ratio 1.24, 95% CI 0.79 to 1.94. 
7 
Suzuki 2001, Albert 2011, and Uzun 2014. 
8 
One of the trials found an increase in the acquisition of macrolide-resistant organisms among patients who received macrolides, whereas the other trial found a decrease in the acquisition of 
macrolide-resistant organisms among patients who received macrolides. 
9 
The data could not be pooled because one of the trials did not report the crude data. Albert 2011 reported the acquisition of macrolide-resistant organisms in 81% of patients who received 
macrolides and 41% of patients who received placebo; Uzun 2014 reported the acquisition of macrolide-resistant organisms in fewer patients who received macrolides than who received placebo 
(6% versus 24%, risk ratio 0.57, 95% CI 0.15 to 2.26). 
10
 A large number of patients did not have quality of life assessed. 
11 Inconsistency: I
2 
= 38%, phet = 0.20. 
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ONLINE SUPPLEMENT 1 
 
 
PREVENTION OF COPD EXACERBATIONS: An European Respiratory Society/American 
Thoracic Society (ERS/ATS) guideline. 
 
Authors: Jadwiga A. Wedzicha (1), Peter M. A. Calverley (2), Richard K. Albert (3), Antonio 
Anzueto (4), Gerard J. Criner (5), John R Hurst (6), Marc Miravitlles (7), Alberto Papi (8), Klaus F. 
Rabe (9), David Rigau (10), Pawel Sliwinski (11), Thomy Tonia (12), Jørgen Vestbo (13), Kevin C. 
Wilson (14), Jerry A. Krishnan (15). 
 
Center: 1. Airways Disease Section, National Heart and Lung Institute, Imperial College 
London, UK. Co-chair, representing European Respiratory Society. 2. Institute of Ageing and 
Chronic Disease, University of Liverpool, Liverpool, UK. 3. Department of Medicine, University 
of Colorado, Denver, Aurora, Colorado, U.S.A. 4. University of Texas Health Science Center and 
South Texas Veterans Health Care System, San Antonio, Texas, U.S.A. 5. Department of 
Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, 
Philadelphia, Pennsylvania, U.S.A. 6. UCL Respiratory, University College London, London, UK. 
7. Pneumology Department, Hospital Universitari Vall d’Hebron. CIBER de Enfermedades 
Respiratorias (CIBERES), Barcelona, Spain. 8. Respiratory Medicine. Department of Medical 
Sciences, University of Ferrara, Ferrara, Italy. 9. Department of Internal Medicine, Christian-
Albrechts University, Kiel and LungenClinic Grosshansdorf, Airway Research Centre North, 
German Centre for Lung Research, Grosshansdorf, Germany. 10. Iberoamerican Cochrane 
Center, Barcelona, Spain. 11. 2nd Department of Respiratory Medicine. Institute of 
Tuberculosis and Lung Diseases, Warsaw, Poland. 12. Institute of Social and Preventive 
Medicine, University of Bern, Bern, Switzerland. 13. Division of Infection, Immunity and 
Respiratory Medicine, University of Manchester, Manchester, UK. 14. Department of 
Medicine, Boston University School of Medicine, Boston, Massachusetts, U.S.A. 15. University 
of Illinois Hospital & Health Sciences System, Chicago, U.S.A.; co-chair, representing American 
Thoracic Society 
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FULL METHODS SECTION 
 
Group composition 
The guideline panel co-chairs (JAW, JAK) were selected by the European Respiratory Society 
(ERS) and American Thoracic Society (ATS). They led all aspects of project management and 
selected the panellists, which included 11 clinicians with experience in COPD management and 
research. In addition, there were two methodologists (TT, DR) and a clinician-methodologist 
(KCW). The lead methodologist (TT) identified and collected the evidence, performed the 
evidence syntheses, constructed the evidence profiles, and ensured that all the 
methodological requirements were met, with assistance from the other methodologists. The 
co-chairs and panellists discussed the evidence and formulated the recommendations; the 
methodologists did not participate in the development of recommendations. All panel 
members were required to disclose their conflicts of interest. At least 50% of the co-chairs and 
50% of the panel were required to be free from conflicts of interest. Individuals with potential 
conflicts of interest took part in the discussions about the evidence but did not participate in 
the formulation of recommendations.  
 
Formulation of questions 
Guideline panel members compiled a list of issues that they considered important and relevant 
to the treatment of COPD exacerbations. The questions were rephrased by the lead 
methodologist using the Population, Intervention, Comparator, and Outcomes (PICO) format 
(1). Discussion and consensus among the co-chairs and panellists was used to identify the six 
questions that would be addressed in the guideline.  
 
Rating the importance of outcomes 
After choosing the questions, the guideline panel identified outcomes that they considered 
relevant to each question prior to conducting the literature search. They rated the importance 
of each outcome using a scale from 1 to 9 (a rating of 1 to 3 was assigned to outcomes of low 
importance for decision-making, 4 to 6 to outcomes important for decision-making, and 7 to 9 
to outcomes critically important for decision-making). A teleconference was convened during 
which the ratings were discussed and some additional outcomes were rated. At the conclusion 
of the teleconference, all outcomes were categorized as “critical”, “important”, or “not 
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important” for decision-making. The reason for the distinction is that only critical outcomes 
are used to determine the overall quality of evidence for a recommendation, even though the 
quality of evidence is assessed for every outcome.  
 
Literature searches 
Our literature searches used the National Institute of Health and Clinical Excellence (NICE) 
guidelines as a starting point (2,3). For questions that were addressed in the 2004 NICE 
guidelines, we conducted literature searches in Medline, Embase, and the Cochrane Database 
of Systematic Reviews beginning in 2003. For questions that were addressed in the 2010 NICE 
guidelines, we conducted literature searches in the same databases beginning in 2009. Initial 
searches were conducted in January 2012 and then updated in June 2012, February 2013, and 
September 2015. We used the same or similar search strategies as those used by NICE. To 
search Embase and Medline, we searched only the English speaking literature using the search 
strategy shown in the online supplement, whereas to search the Cochrane Database of 
Systematic Reviews, we used the search term, “chronic obstructive pulmonary disease”. 
 
Study selection  
The lead methodologist screened the titles and abstracts of the retrieved studies and excluded 
studies on the basis of the pre-defined study selection criteria shown in the online 
supplement. For those studies that could not be excluded by the title and abstract, we 
obtained the full text of the studies and then included or excluded the studies on the basis of 
our full text review. In cases of uncertainty, the opinions of the co-chairs and panellists were 
obtained and decisions were reached by discussion and consensus. We also screened the 
reference lists from recent and well-conducted systematic reviews, in order to ensure that our 
literature review had not missed any relevant studies.  
 
Evidence synthesis 
Study characteristics, types of participants, interventions, the outcomes measured, and results 
were extracted from each study. If the data was amendable to pooling, effects were estimated 
via meta-analysis using Review Manager (4). For the meta-analyses, the random effects model 
was utilized unless otherwise specified. Dichotomous outcomes were reported as relative risks 
and continuous outcomes were reported as mean differences unless otherwise specified. The 
lead methodologist appraised the quality of evidence using the Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE) approach (5-12). 
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The lead methodologist used GRADEpro to develop evidence profiles that summarized the 
findings for each outcome and the rationale for the quality of evidence appraisal (13-15). 
Thresholds for clinically important differences between treatment groups (used to judge 
imprecision) included the following relative risk reductions: mortality 15%, exacerbations 20%, 
hospitalizations 20%, and adverse events 15%. They also included the following absolute 
reduction: St. George’s Respiratory Questionnaire score change of 4 points.  
 
Formulating and grading recommendations 
The evidence profiles were sent to the guideline panel members for review. Using an iterative 
consensus process conducted primarily by email, but also via teleconference and face-to-face 
meetings, recommendations were formulated on the basis of the following considerations: the 
balance of desirable (benefits) and undesirable consequences (burden, adverse effects, cost) 
of the intervention, the quality of evidence, patient values and preferences, and feasibility 
(16). 
 
A strong recommendation would have been made for an intervention if the panel was certain 
that the desirable consequences of the intervention outweigh the undesirable consequences, 
just as a strong recommendation would have been made against an intervention if the panel 
was certain that the undesirable consequences of the intervention outweigh the desirable 
consequences. A strong recommendation would have indicated that most well-informed 
patients would choose to have or not to have the intervention.  
 
A conditional recommendation was made for an intervention when the panel was uncertain 
that the desirable consequences of the intervention outweigh the undesirable consequences, 
just as a conditional recommendation was made against an intervention if the panel was 
uncertain that the undesirable consequences of the intervention outweigh the desirable 
consequences. Reasons for uncertainty included low or very low overall quality of evidence 
(determined from the outcomes a priori defined as “critical”), the desirable and undesirable 
consequences being finely balanced, or the underlying values and preferences playing an 
important role. A conditional recommendation indicates that well-informed patients may 
make different choices regarding whether to have or not have the intervention.  
 
Manuscript preparation 
The initial draft of the manuscript was prepared by the co-chairs, methodologists, and one 
panellist (MM). The lead methodologist wrote the content for the online supplement, which 
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was edited by the co-chairs. Both the manuscript and the online supplement were reviewed, 
edited, and approved by all panel members prior to submission.  
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